BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm updated its model for fiscal Q3 financials and lowered peak sales estimates for first-gen ‘1401 in myasthenia gravis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant price target lowered to $44 from $46 at Guggenheim
- Immunovant’s Strategic Positioning and Financial Strength Propel IMVT-1402 Towards Pivotal Studies
- Immunovant management to meet with Piper Sandler
- Immunovant Reports Progress Amid Increased R&D Costs
- Immunovant’s Promising Pipeline and Strategic Advancements Reinforce Buy Recommendation